Sangamo’s hemophilia A gene therapy giroctocogene fitelparvovec, now overseen by Pfizer, leads a pipeline of 17 wholly-owned and partnered genomic medicines—four in clinical phases; the rest, preclinical . . .
The post Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’ appeared first on GEN – Genetic Engineering and Biotechnology News.
